# Anaptysbio, Inc: overview ANAB · Nasdaq · CIK 1370053 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jun 30 Pages: [Overview](/companies/anab.md) · [Financials](/companies/anab/financials.md) · [Filings](/companies/anab/filings.md) · [Insiders](/companies/anab/insiders.md) Latest reported revenue: [$27.5m](/filings/0001193125-26-396696.md) for Q2 FY2026, three months to 2026-06-30, from the 10-KT filed Sep 21, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-396696). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [30.0](/filings/0001370053-25-000089.md) | [43.1 d](/filings/0001193125-26-396696.md) | [27.8](/filings/0001193125-26-219515.md) | [22.3](/filings/0001370053-25-000064.md) | [76.3](/filings/0001370053-25-000089.md) | [108 d](/filings/0001193125-26-396696.md) | [25.6](/filings/0001193125-26-219515.md) | [27.5 d](/filings/0001193125-26-396696.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(75.8%)](/filings/0001370053-25-000089.md) | [397.6% d](/filings/0001193125-26-396696.md) | [(99.2%)](/filings/0001193125-26-219515.md) | [(117.5%)](/filings/0001370053-25-000064.md) | [45.5%](/filings/0001370053-25-000089.md) | [227.2% d](/filings/0001193125-26-396696.md) | [(135.5%)](/filings/0001193125-26-219515.md) | [243.6% d](/filings/0001193125-26-396696.md) | | Net margin | % | [(109.4%)](/filings/0001370053-25-000089.md) | [(50.5%) d](/filings/0001193125-26-396696.md) | [(141.6%)](/filings/0001193125-26-219515.md) | [(173.5%)](/filings/0001370053-25-000089.md) | [19.8%](/filings/0001370053-25-000089.md) | [45.8% d](/filings/0001193125-26-396696.md) | [(206.9%)](/filings/0001193125-26-219515.md) | [668.9% d](/filings/0001193125-26-396696.md) | | Diluted EPS | $ per share | [(1.14)](/filings/0001370053-25-000089.md) | not reported | [(1.28)](/filings/0001193125-26-219515.md) | [(1.34)](/filings/0001370053-25-000064.md) | [0.52](/filings/0001370053-25-000089.md) | not reported | [(1.84)](/filings/0001193125-26-219515.md) | not reported | | Free cash flow | $m | [(10.1) d](/filings/0001370053-25-000089.md) | [(66.9) d](/filings/0001193125-26-396696.md) | [(10.7)](/filings/0001193125-26-219515.md) | [(40.3) d](/filings/0001193125-26-396696.md) | [(27.4) d](/filings/0001370053-25-000089.md) | [98.0 d](/filings/0001193125-26-396696.md) | [(25.9)](/filings/0001193125-26-219515.md) | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [63.2](/filings/0001370053-24-000011.md) | [10.3](/filings/0001370053-25-000024.md) | [17.2](/filings/0001193125-26-088290.md) | [91.3](/filings/0001193125-26-396696.md) | [235](/filings/0001193125-26-396696.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(89.9%)](/filings/0001370053-24-000011.md) | [(1119.4%)](/filings/0001370053-25-000024.md) | [(958.3%)](/filings/0001193125-26-088290.md) | [72.5%](/filings/0001193125-26-396696.md) | [96.7%](/filings/0001193125-26-396696.md) | | Net margin | % | [(91.5%)](/filings/0001370053-24-000011.md) | [(1251.3%)](/filings/0001370053-25-000024.md) | [(953.7%)](/filings/0001193125-26-187044.md) | [(159.1%)](/filings/0001193125-26-396696.md) | [(5.6%)](/filings/0001193125-26-396696.md) | | Diluted EPS | $ per share | [(2.11)](/filings/0001370053-24-000011.md) | [(4.57)](/filings/0001370053-25-000024.md) | [(6.08)](/filings/0001193125-26-088290.md) | [(4.92)](/filings/0001193125-26-396696.md) | [(0.44)](/filings/0001193125-26-396696.md) | | Free cash flow | $m | [(47.3)](/filings/0001370053-24-000011.md) | [(74.0)](/filings/0001370053-25-000024.md) | [(122)](/filings/0001193125-26-088290.md) | [(136)](/filings/0001193125-26-396696.md) | [19.6](/filings/0001193125-26-396696.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/anab/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [EcoR1 Capital, LLC](/funds/1587114.md) | 2026-06-30 | $531.9m | 7,880,094 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $124.5m | 1,844,049 | | Added +162,669 | | [TANG CAPITAL MANAGEMENT LLC](/funds/1232621.md) | 2026-06-30 | $89.8m | 1,330,879 | | Unchanged | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $86.8m | 1,286,194 | | Added +293,749 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $61.2m | 906,233 | | Added +53,082 | | [Affinity Asset Advisors, LLC](/funds/1773195.md) | 2026-06-30 | $55.8m | 826,109 | | Reduced −113,891 | | [Sanofi](/funds/1121404.md) | 2026-06-30 | $55.5m | 821,917 | | Unchanged | | [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $54.5m | 807,316 | | Added +331,744 | | [Woodline Partners LP](/funds/1784547.md) | 2026-06-30 | $48.4m | 717,014 | | Added +372,758 | | [683 Capital Management, LLC](/funds/1404574.md) | 2026-06-30 | $44.6m | 660,000 | | Added +35,000 | ## Recent filings [All 704 filings](/companies/anab/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-21 | 20:20 ET | [8-K](/filings/0001193125-26-396690.md) | 9.01 Financial statements and exhibits | 0001193125-26-396690 | | 2026-08-11 | 20:05 ET | [8-K](/filings/0001193125-26-344583.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-344583 | | 2026-07-30 | 20:05 ET | [8-K](/filings/0001193125-26-326097.md) | 7.01 Regulation FD disclosure | 0001193125-26-326097 | | 2026-06-29 | 20:05 ET | [DEF 14A](/filings/0001193125-26-288408.md) | Proxy statement, period 2026-06-29 | 0001193125-26-288408 | | 2026-06-22 | 20:05 ET | [8-K](/filings/0001193125-26-277505.md) | 1.01 Entry into a material agreement | 0001193125-26-277505 | | 2026-05-29 | 20:15 ET | [8-K](/filings/0001193125-26-248326.md) | 7.01 Regulation FD disclosure | 0001193125-26-248326 | | 2026-05-21 | 20:10 ET | [8-K](/filings/0001193125-26-234419.md) | 5.03 Amendment to articles or bylaws | 0001193125-26-234419 | | 2026-05-12 | 20:20 ET | [10-Q](/filings/0001193125-26-219515.md) | Quarterly report, period 2026-03-31 | 0001193125-26-219515 | | 2026-05-12 | 20:17 ET | [8-K](/filings/0001193125-26-219500.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-219500 | | 2026-05-11 | 20:05 ET | [8-K](/filings/0001193125-26-216745.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-216745 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-088290.md), filed Mar 3, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/a00feef6-42fc-4a8d-9136-17fc9d5e4342) ## About the filer - CIK: 1370053 - Tickers: ANAB - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:38 ET. No prices; not investment advice.